Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05401786
Title Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)
Acronym RAD-IO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors The Netherlands Cancer Institute
Age Groups: adult | senior
Covered Countries NLD

Additional content available in CKB BOOST